OUR PIPELINE
Accelerating development of first-in-class drug candidates
Our degraders and degrader antibody conjugates are designed to eliminate pathogenic proteins, an approach with the potential to overcome the limitations of current treatments and more effectively disrupt disease processes.
CLINICAL TRIALS
Advancing novel medicines for cancer and autoimmune disease
Our strong scientific and translational capabilities enable us to rapidly advance assets from the lab bench to the clinic, as we pursue novel therapies for cancer and autoimmune diseases that have the potential to provide patients with safer, deeper, and more durable responses for sustained disease control.